Physiologic Response to the Pfizer-BioNTech COVID-19 Vaccine Measured Using Wearable Devices: Prospective Observational Study.
Physiologic Response to the Pfizer-BioNTech COVID-19 Vaccine Measured Using Wearable Devices: Prospective Observational Study.
复制标题
DOI：
10.2196/28568
复制
发表时间：
2021-08-04
影响因子：
2.2
通讯作者：
Tinsley A
中科院分区：
文献类型：
--
作者：
Hajduczok AG;DiJoseph KM;Bent B;Thorp AK;Mullholand JB;MacKay SA;Barik S;Coleman JJ;Paules CI;Tinsley A
辉瑞- biontech公司的COVID-19疫苗使用一种新的信使RNA技术来引发保护性免疫反应。尚未使用可穿戴设备研究疫苗的短期生理反应。我们的目标是在使用可穿戴设备（WHOOP Strap 3.0）的一小群参与者中描述COVID-19疫苗接种后的生理变化。这是使用消费级可穿戴设备监测COVID-19疫苗反应的概念验证。在这项前瞻性观察研究中，使用WHOOP Strap 3.0收集了来自同一机构的19名接受了两剂辉瑞- biontech COVID-19疫苗的内科住院医生的生理数据。主要结局是心率变异性（HRV）、静息心率（RHR）和呼吸频率（RR）与基线相比的百分比变化。次要结果是与基线相比的总体变化百分比、快速眼动和深度睡眠。探索性结果包括每次剂量和预防性止痛药使用后的局部和全身反应性。19例患者（平均年龄28.8岁，SD 2.2岁；n=10，女性53%），HRV在接种第一剂疫苗（平均-13.44%,SD 13.62%）和第二剂疫苗（平均-9.25%,SD 22.6%）后第1天下降。两种疫苗接种后，RHR和RR与基线没有变化。在接种疫苗后第1天睡眠时间减少后，睡眠时间增加至接种后4天。疫苗接种前睡眠时间的增加与HRV的较大变化有关。第二次剂量后，局部和全身反应性更为严重。这是首次使用可穿戴设备测量对任何新型COVID-19疫苗的生理反应的观察性研究。使用这个相对较小的健康队列，我们提供的证据表明，HRV对两种疫苗剂量的反应都有所降低，而RHR或RR没有显著变化。每次给药后，睡眠时间开始减少，随后增加。未来的研究需要更大的样本量，并与其他炎症和免疫生物标志物（如抗体反应）进行比较，以确定这种类型的连续可穿戴监测在疫苗反应方面的真正效用。我们的数据提出了疫苗接种前增加睡眠可能会影响生理反应的可能性，并且可能是一种可修改的方式来增加疫苗反应。这些结果可能为未来使用可穿戴设备监测疫苗反应的研究提供信息。ClinicalTrials.gov NCT04304703;https://www.clinicaltrials.gov/ct2/show/NCT04304703
The Pfizer-BioNTech COVID-19 vaccine uses a novel messenger RNA technology to elicit a protective immune response. Short-term physiologic responses to the vaccine have not been studied using wearable devices. We aim to characterize physiologic changes in response to COVID-19 vaccination in a small cohort of participants using a wearable device (WHOOP Strap 3.0). This is a proof of concept for using consumer-grade wearable devices to monitor response to COVID-19 vaccines. In this prospective observational study, physiologic data from 19 internal medicine residents at a single institution that received both doses of the Pfizer-BioNTech COVID-19 vaccine was collected using the WHOOP Strap 3.0. The primary outcomes were percent change from baseline in heart rate variability (HRV), resting heart rate (RHR), and respiratory rate (RR). Secondary outcomes were percent change from baseline in total, rapid eye movement, and deep sleep. Exploratory outcomes included local and systemic reactogenicity following each dose and prophylactic analgesic use. In 19 individuals (mean age 28.8, SD 2.2 years; n=10, 53% female), HRV was decreased on day 1 following administration of the first vaccine dose (mean –13.44%, SD 13.62%) and second vaccine dose (mean –9.25%, SD 22.6%). RHR and RR showed no change from baseline after either vaccine dose. Sleep duration was increased up to 4 days post vaccination, after an initial decrease on day 1. Increased sleep duration prior to vaccination was associated with a greater change in HRV. Local and systemic reactogenicity was more severe after dose two. This is the first observational study of the physiologic response to any of the novel COVID-19 vaccines as measured using wearable devices. Using this relatively small healthy cohort, we provide evidence that HRV decreases in response to both vaccine doses, with no significant changes in RHR or RR. Sleep duration initially decreased following each dose with a subsequent increase thereafter. Future studies with a larger sample size and comparison to other inflammatory and immune biomarkers such as antibody response will be needed to determine the true utility of this type of continuous wearable monitoring in regards to vaccine responses. Our data raises the possibility that increased sleep prior to vaccination may impact physiologic responses and may be a modifiable way to increase vaccine response. These results may inform future studies using wearables for monitoring vaccine responses. ClinicalTrials.gov NCT04304703; https://www.clinicaltrials.gov/ct2/show/NCT04304703
登录
查看更多内容
DOI：
10.1038/nrd.2017.243
发表时间：
2018-04
期刊：
Nature reviews. Drug discovery
影响因子：
--
作者：
Pardi N;Hogan MJ;Porter FW;Weissman D
通讯作者：
Weissman D
影响因子：
1.2
作者：
Hasty F;García G;Dávila H;Wittels SH;Hendricks S;Chong S
通讯作者：
Chong S
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
3.7
作者：
de Castilho FM;Ribeiro ALP;Nobre V;Barros G;de Sousa MR
通讯作者：
de Sousa MR
影响因子：
4
作者：
Herzig D;Eser P;Omlin X;Riener R;Wilhelm M;Achermann P
通讯作者：
Achermann P